

## AUTHOR INDEX

- Aboukameel, A., 313  
 Adamia, S., 165  
 Aguilera, C., 187  
 Ahles, T., 749  
 Ahuja, R., 94  
 Al-Katib, A., 110  
 Al-Katib, A.M., 313  
 Aleman, A., 286  
 Alexanian, R., 116, 206, 243  
 Amess, J.A.L.A., 236  
 Amols, H.I., 596  
 Anagnostopoulos, A., 121  
 Anagnostopoulos, N., 265, 286  
 Anderson, C.M., 369  
 Anderson, K., 121  
 Anderson, K.C., 156, 248, 309  
 Angelopoulou, M.K., 201  
 Arriagada, R., 38  
 Avet-Loiseau, H., 153  
 Aymerich, M., 178  
 Azzoli, C.G., 79
- Báñez, A., 187  
 Bagnell, S., 587  
 Baldini, L., 211  
 Bander, N.H., 667  
 Barbarano, L., 172  
 Barlogie, B., 116, 220, 282  
 Barrans, S.L., 161  
 Bartlett, N.L., 448  
 Bataille, R., 153  
 Bay, J.O., 291  
 Belch, A.R., 132, 165  
 Bennett, B.L., 275  
 Bernuzzi, P., 231  
 Björkholm, M., 116, 226  
 Bladé, J., 127, 178, 329  
 Blum, K.A., 448  
 Bosch, F., 178  
 Branagan, A.R., 110, 116, 121, 127  
 Broglia, C., 211  
 Bruenke, J., 465  
 Bruner, R.J., 509  
 Bugge, T.A., 545  
 Burman, C.M., 596  
 Burstein, H.J., 817  
 Byrd, J.C., 127, 421, 483
- Cabanillas, F., 206  
 Cahn, J.Y., 291  
 Canesi, B., 172  
 Carducci, M.A., 678  
 Carrotte-Lefebvre, I., 216  
 Cavanna, L., 172  
 Cazin, B., 216, 291  
 Celsing, F., 226  
 Cesana, C., 172, 231  
 Cesano, A., 253, 457  
 Chirgwin, J.M., 717
- Chlebowski, R.T., 776  
 Cho, D., 567  
 Choquet, S., 239  
 Christianson, D.F., 369  
 Chui, C-S., 596  
 Col, N.F., 776  
 Coleman, M., 121, 270, 457  
 Colomer, D., 424  
 Comelli, M., 211  
 Crainie, M., 165  
 Crowley, J.J., 220  
 Cuello, R., 187  
 Curtin, J.P., 401
- D'Avanzo, G., 231  
 Davidson, N.E., 338  
 Dechant, M., 465  
 Delasalle, K., 206, 243  
 Demark-Wahnefried, W., 789  
 Desablens, B., 291  
 Detournignies, L., 216  
 Dhodapkar, M., 116  
 Dhodapkar, M.V., 220, 305  
 Di Blasio, C.J., 567  
 Dillman, R.O., 434  
 Dimopoulos, M., 107, 206  
 Dimopoulos, M.A., 110, 243, 265  
 Dimopoulou, M.N., 201  
 DiPaolo, R.S., 390  
 Divine, M., 291  
 Doll, D.C., 337  
 Dreyfus, B., 291
- Eberhardt, S.C., 616  
 Economopoulos, T., 265  
 Emens, L.A., 338  
 Emmanouilides, C., 127, 248, 258, 531  
 Epstein, K.R., 86  
 Erridge, S.C., 26  
 Escribano, L., 187  
 Esteve, J., 178
- Farag, S.S., 509  
 Ferrer, A., 178  
 Filippini, D., 231  
 Flinn, I.W., 520  
 Fong, L., 649  
 Fonseca, R., 110, 142  
 Forconi, F., 136  
 Frankel, A.E., 545  
 Frankel, S., 248  
 Frankel, S.R., 121, 300  
 Fuks, Z., 596
- Galsky, M., 689  
 Garand, R., 153  
 García-Frade, J., 187  
 Gavino, M., 243  
 Gayko, U., 253
- Gerald, W.L., 635  
 Gertz, M.A., 121, 220, 325  
 Giné, E., 178  
 Ginsberg, R.J., 47  
 Giral, S., 121, 286  
 Glisson, B.S., 72  
 Gobbi, P.G., 211  
 Goldaniga, M., 211  
 Goldenberg, D.M., 457  
 Goldsmith, S.J., 667  
 Gomez, J., 79  
 Gregor, P.D., 659  
 Greipp, P.R., 110, 262  
 Gressin, R., 291  
 Guise, T.A., 717
- Hamilos, G., 265  
 Hanson, C.A., 182  
 Hayman, S., 262  
 Hernández, J., 187  
 Hillmen, P., 493  
 Hodnefield, J.M., 182  
 Hricak, H., 616  
 Hunt, M., 596
- Jack, A.S., 161  
 Jackson, A., 596  
 Jacobson, J.L., 220  
 Jahrsörfer, B., 476  
 Johansson, E., 226
- Kantoff, P.W., 698  
 Kattan, M.W., 567  
 Keele, B., 248  
 Kelliher, A., 248  
 Kelly, W.K., 689  
 Kim, J.A., 776  
 Kimby, E., 127, 248  
 Kittas, C., 201  
 Klersy, C., 172  
 Klotz, L., 587  
 Kondagunta, G.V., 382  
 Kontopidou, F.N., 201  
 Kornblith, A.B., 799  
 Kostakoglu, L., 667  
 Kreitman, R.J., 545  
 Kriangkum, J., 132, 165  
 Kris, M.G., 79  
 Krug, L.M., 1, 79  
 Kurtin, P.J., 182  
 Kyle, R.A., 107, 116, 169, 182, 325  
 Kyrtsonis, M-C., 201
- López, R., 187  
 López-Guillermo, A., 178  
 Lambertenghi, G., 211  
 Larson, D.R., 169  
 Lassiter, L.K., 678  
 Lazzarino, M., 172

- Le Pêchoux, C., 38  
 Leblond, V., 116, 216, 239, 291  
 Leibel, S.A., 596  
 Leibowitz, S.B., 698  
 Leitch, D., 161  
 Leonard, J., 270  
 Leonard, J.P., 457  
 Leone, F.T., 94  
 Leppla, S.H., 545  
 Levine, T., 121  
 Ligibel, J., 799  
 Lin, T.S., 483  
 Ling, C.C., 596  
 Link, B.K., 375  
 Lis, E., 616  
 Lister, T.A., 116, 226, 236  
 Lodé, L., 153  
 Logothetis, C.J., 562  
 Lucas, M.S., 483  
 Lyons, L., 270  
  
 Mageras, G.S., 596  
 Malek, S.N., 520  
 Mant, M.J., 132, 165  
 Margaritis, D., 265  
 Mateo, G., 187  
 Matesich, M.A., 740  
 Matsouka, C., 265  
 Matthews, J., 226  
 Mayer, R.J., 349  
 McElroy, Y.G., 318  
 McMaster, M.L., 110, 146  
 Melton, L.J. III, 169  
 Mensah-Osman, E., 313  
 Mercurio, F., 275  
 Merlini, G., 116, 211  
 Meyerhardt, J.A., 349  
 Miller, V.A., 1, 79  
 Milowsky, M.I., 667  
 Milpied, N., 291  
 Miqueleiz, S., 231  
 Mitsiades, C., 248  
 Mitsiades, C.S., 156, 309  
 Mitsiades, N., 156, 248, 309  
 Mohammad, R., 313  
 Montoto, S., 178, 329  
 Montserrat, E., 178, 329, 424  
 Morel, P., 116, 216  
 Moreton, P., 493  
 Moro, M.J., 187  
 Morra, E., 110, 172, 231  
 Motzer, R.J., 382  
 Munshi, N., 121  
 Munshi, N.C., 282  
 Murray, N., 26  
  
 Nadal, E., 178  
 Nanus, D.M., 667  
 Neville, D.M., 545  
 Newman, J.T., 318  
 Ngan, S., 236  
  
 Nichols, G.L., 297  
 Niesvizky, R., 270  
 Nordquist, L.T., 659  
 Norton, A., 236  
  
 Ocio, E., 187  
 Offord, J.R., 169  
 Onyebuchi, C.N., 616  
 Orfao, A., 187  
 Ottensmeier, C.H., 136  
 Owen, R.G., 110, 161, 196  
  
 Palladini, G., 211  
 Panayiotidis, P., 265  
 Pangalis, G.A., 110, 201  
 Papamichael, D., 226  
 Partridge, A.H., 817  
 Paskett, E.D., 814  
 Patel, J.D., 79  
 Patel, S.R., 413  
 Perrier, J.F., 291  
 Pestronk, A., 121, 318  
 Pignon, B., 291  
 Pilarski, L.M., 132, 165  
 Pisters, P.W.T., 413  
 Plevak, M.F., 169  
 Portero, J., 187  
 Preffer, F., 248  
 Pucar, D., 616  
  
 Rajkumar, S.V., 169, 262  
 Rajkumar, V., 121  
 Ramaswamy, B., 763  
 Rankin, K., 243  
 Remstein, E.D., 182  
 Reynolds, J.L., 318  
 Rhee, A.C., 567  
 Richardson, P.G., 309  
 Robillard, N., 153  
 Rock, C.L., 789  
 Rohatiner, A.Z.S., 226, 236  
 Rose, C., 216  
 Rosen, N., 709  
 Rosiñol, L., 178, 329  
 Rossi, V., 231  
 Rozman, M., 178  
 Rugo, H.S., 749  
  
 Sánchez, M.L., 187  
 Sánchez-Guijo, F., 187  
 Sahota, S.S., 136  
 Salgia, R., 57  
 San Miguel, J.F., 110, 187  
 Sandler, A.B., 9  
 Sattler, M., 57  
 Scardino, P.T., 567  
 Schöeder, H., 616  
 Schafer, P.H., 275  
 Scher, H.I., 616, 659, 709  
 Schlossman, R., 248  
 Schop, R.F.J., 142  
  
 Seidman, A.D., 730  
 Senecal, D., 291  
 Shahab, N., 337  
 Shapiro, C.L., 729, 740, 763  
 Sheinfeld, J., 382  
 Shepherd, F.A., 47  
 Siakantaris, M.P., 201  
 Siegel, A.B., 457  
 Slovin, S.F., 561, 659  
 Small, E.J., 649  
 Smith, T.J., 361  
 Solit, D.B., 709  
 Stalnikiewicz, L., 216  
 Stein, C.A., 297  
 Stevenson, F.K., 136  
 Stirling, D.I., 275  
 Stone, M., 116  
 Stone, M.J., 318  
 Szczesna, A., 47  
 Szczesny, T.J., 47  
 Szelenyi, H., 270  
  
 Tabrizi, R., 291  
 Tallman, M.S., 502  
 Taylor, B.J., 132  
 Theodoulou, M., 730  
 Therneau, T.M., 169  
 Tomblyn, M.R., 502  
 Tong, A.W., 318  
 Tournihac, O., 291  
 Travade, P., 291  
 Treon, S.P., 107, 110, 116, 121, 127, 132, 156, 248, 309  
 Tresoldi, E., 172, 231  
 Tsatalas, C., 265  
  
 Vaidya, A.P., 401  
 Valerius, T., 465  
 Vallabhaajosula, S., 667  
 Varettoni, M., 172  
 Vassilakopoulos, T.P., 201  
 Vidriales, M.B., 187  
 Villamor, N., 424  
 Vinés, E.F., 38  
  
 Weber, D., 127, 206  
 Weber, D.M., 243  
 Weibel, S.B., 94  
 Weiner, G.J., 476  
 William, A., 236  
 Winer, E.P., 729, 817  
 Wolchok, J.D., 659  
 Wooldridge, J.E., 337, 375  
  
 Yao, S.-L., 390  
  
 Zagars, G.K., 413  
 Zakowski, M.F., 3  
 Zeldis, J.B., 275  
 Zelefsky, M.J., 596  
 Zomas, A., 265

## SUBJECT INDEX

- Accuracy, 573-574  
 ACE chemotherapy regimen, in small cell lung cancer, 14-15  
 Acetate, 625  
 ACTIMID, 276  
 Actin cytoskeleton, in lung cancer, 64-65  
 Acute myeloid leukemia, incidence of, 502  
 Acute radiation-associated pericarditis, following early breast cancer therapy, 731  
 Age, stem cell transplantation and, 287-288  
 Albumin, serum, as prognostic factor, in Waldenstrom's macroglobulinemia, 214-215  
 Alcohol, breast cancer and, 794  
 Alemtuzumab, 248-249, 422, 424, 429  
   administration of, 498  
   in B-cell malignancies, 494-495  
   in combination therapy, 496-497  
   dosing of, 443-444  
   hematological toxicity of, 498  
   infusion-related side effects of, 497  
   mechanism of, 498  
   mechanism of action of, 429-430  
   in non-Hodgkin's lymphoma, 495-496  
 All-trans retinoic acid, 506  
 Alpha-carotene, chemical structure of, 87  
 Alzheimer's disease, 755  
 American Gastroenterological Association, recommendations of, in colorectal cancer recurrence, 356-357  
 American Society for Therapeutic Radiation and Oncology consensus, in prostate specific antigen relapse, 568-569  
 American Society of Clinical Oncology  
   lung cancer follow-up guidelines of, 363, 364  
   recommendations of, in colorectal cancer recurrence, 356-357  
 Amyloidosis, 124  
   with monoclonal immunoglobulin M protein, 325-327  
 Anastrozole, 769-770  
 Androgen ablation therapy, in prostate cancer, 394-395  
 Androgen deprivation  
   intensity-modulated radiotherapy and, 611-612  
   radiotherapy and, 609-612  
   three-dimensional conformal radiotherapy and, 611-612  
 Androgen receptor, heat shock protein and, 710-711  
 Anemia, as prognostic factor, in Waldenstrom's macroglobulinemia, 218-219  
 Angiogenesis  
   in prostate cancer, 679  
   in Waldenstrom's macroglobulinemia, 262-263  
 Angiogenic growth factor, in prostate cancer, 589  
 Animal model, in human leukocyte antigen class II antibody trials, 468-470  
 Annexin V, 428  
 Ansamycin, clinical trials of, 713-714  
 Anthracycline(s)  
   cardiac toxicity of, 732-735  
   cardiotoxicity of, 735  
   liposomal, 736-737  
 Anti-B1, 429  
 Anti-CD3, 422, 551  
 Anti-CD20, radioisotope conjugates of, 488-489  
 Anti-CD20 therapy, 425-429  
 Anti-CD22 monoclonal antibodies  
   clinical applications of, 255-256  
   as therapeutic agents, 255  
 Anti-CD33 therapy, 430  
 Anti-CD52 therapy, 429-430  
   mechanism of resistance to, 430  
 Anti-CD55 monoclonal antibodies, 427  
 Anti-CD59 monoclonal antibodies, 427  
 Anti-CD7, 551  
 Anti-nuclear antibody, 318-323  
 Anti-transferrin receptor immunoconjugates, potency of, 549  
 Antibody dependent-cell mediated cytotoxicity, 425  
   rituximab and, 425-426  
 Anticarcinogenic substances, lung cancer and, 88  
 Anticytokine, 422  
 Antigen, in small cell lung cancer, 82  
 Antigen presenting cell, 650-651, 662  
 Antisense BCL-2, in small cell lung cancer, 76  
 Antithymocyte globulin, 510  
 Apolipoprotein E, 755  
 Apolizumab, 454  
 Apoptosis, 472  
   forward side scatter in, 427  
   in prostate cancer, 679  
   rituximab and, 428-429  
   side scatter in, 427  
 Aromatase, 769-770  
 Arrhythmia, following systemic chemotherapy, 732  
 Artifact, crush, 5  
 Atrasentan, 678  
   clinical responses to, 682  
   toxicities of, 682  
 Attention, following chemotherapy, 750  
 Autocrine growth loop, in small cell lung cancer, 75  
 Autologous bone marrow transplant, in small cell lung cancer chemotherapy, 15  
 AZD 4054, 678  
  
 B-chronic lymphocytic leukemia, treatment of, autoimmune complications in, 488  
 B43-PAP, 551  
 BA 12-9566, 81  
 Basic fibroblast growth factor, in prostate cancer, 589  
 bcl-2, 589  
   in small cell lung cancer, 76  
 bcl-2 antisense, cell death and, 301  
 bcl-2 antisense therapy, in Waldenstrom's macroglobulinemia, 297-299  
 BCL-2 gene, in lung cancer, 58-59  
 bcl-10, 163  
 Bellergal, 782  
 Bence Jones protein, quantification of, 129-130  
 Benign prostate hyperplasia, 396  
 Beta-2 microglobulin  
   as prognostic factor, 214-215

- Beta-2 microglobulin (*Continued*)  
 levels of, 207, 209
- Beta-carotene, 793  
 chemical structure of, 87
- Beta-cryptoxanthin, chemical structure of, 87
- Beta-emitter, properties of, 671
- Bexxar, 258
- Biomarker, in prostate cancer, 589-590
- Biopsy, endomyocardial, in cardiotoxicity, 734
- Bisphosphonates  
 actions of, 718-719  
 bone loss and, 721  
 cancer pain and, 720  
 effects of, on tumor, 720-721  
 prostate cancer and, 720  
 role of, in clinic, 719-720
- BL22, 550-551
- Black cohosh, 782
- Blood pressure changes, following systemic chemotherapy, 732
- Blue cell, 5
- Bone, remodeling of, markers of, 717-718
- Bone loss  
 chemotherapy-induced, 732, 766-767  
 ovarian failure and, 767
- Bone metastasis, in prostate cancer, 626-630
- Bone mineral density, 763  
 breast cancer risk and, 764  
 raloxifene and, 768  
 tamoxifen and, 768
- Bone scan, 626-630  
 in breast cancer surveillance, 342-343
- Bone scan index, 627-628
- Bone scan study, in prostate cancer, 622
- Bone scintigraphy, in prostate cancer, 621
- Bone-derived growth factor, 718
- Bootstrapping, 574
- Bosentan, 678
- Brachytherapy, 577-578  
 complications of, 582  
 contraindications to, 580  
 disadvantages of, 581
- Brain metastasis, in small cell lung cancer, 38
- Breast, reconstruction of, 802
- Breast cancer  
 adjuvant chemotherapy of, 821  
 adjuvant therapy of, long-term effects of, 820  
 contralateral disease following, 817-819  
 diet and, 792-795  
 early-stage, overview of, 729  
 empowerment following, 814-816  
 estrogen and, 777-778  
 estrogen deficiency management in, 781-785  
 estrogen plus progestin and, 778-780  
 fertility issues following, 821-822  
 follow-up care following, 818  
 future research directions following, 808-810  
 hormonal therapy of, 821  
 hormone-replacement therapy and, 822-823  
 incidence of, 338, 730, 817  
 increased prevalence of, 338-339
- Breast cancer (*Continued*)  
 lactation following, 822  
 local therapy complications in, 819-820  
 medical sequelae following, 806-807  
 obesity and, 789-792  
 positive psychological consequences following, 807  
 post-traumatic stress disorder and, 801  
 premenopausal, ovarian suppression in, 778  
 psychosocial adjustment following, 799-807  
 psychosocial interventions following, 807-808  
 psychosocial sequelae of, 823  
 radiotherapy for, second cancer following, 742, 743  
 recurrent, 817-819  
 relationships following, 804-805  
 risk of, and bone mineral density, 764  
 sexual functioning and, 802-804  
 stage of, and tumor markers, 341  
 support following, 805  
 survivors of, menopausal hormone therapy in, 780-781
- Breast cancer relapse  
 menopause and, 339  
 patterns of, 339-343  
 screening for, 340  
 signs and symptoms of, 340  
 timing of, 339
- Breast cancer surveillance  
 centralized v decentralized, 344-346  
 clinical trials of, 343  
 evidence-based, 346
- Bupropion, 98
- Bupropion SR, 99-100
- Buserelin, 777-778
- C-Kit, in lung cancer, 60
- C-Met, in lung cancer, 60-62
- C3, 426
- C9, 426
- C138, 133
- CA-125, 410-411  
 following ovarian cancer, 402-403
- CA15-3, breast cancer stage and, 341-342
- CA27-29, breast cancer stage and, 341-342
- Calcitriol, 692, 698-701  
 dosing of, 701-702
- Calibration, 573  
 definition of, 572
- Campath-1, 493-494  
 graft-versus-host disease and, 511-513
- Campath-1H, 454
- Cancer tumor  
 accelerated repopulation of, and chemoradiation, 28-29, 32  
 post-treatment, surveillance in, 337
- Cancer Genome Anatomy Project, 639
- Cancer prevention  
 carotenoid supplementation and, 89-91  
 nutritional substances for, 87-89
- Cancer vaccine, *see* Tumor vaccine
- Capromab pendetide, 668
- Carbohydrate vaccine, 660-661
- Carboplatin, cognitive effects following, 751
- Carboplatin, paclitaxel regimen, in small cell lung cancer, 75

- Carboplatin, cyclophosphamide, thiotepa regimen, cardiac effects of, 731
- Carcinoembryonic antigen testing
  - breast cancer stage and, 341-342
  - colorectal cancer recurrence and, 351
- Carcinoid tumorlet, 6
- Cardiac dysfunction, following systemic chemotherapy, 732
- Cardiac failure, following systemic chemotherapy, 732
- Cardiac toxicity
  - of adjuvant doxorubicin, radiation therapy regimen, 731
  - of adjuvant therapy, in early breast cancer, 731
  - of anthracycline, 732-735
  - of radiation therapy, following breast-conserving surgery, 730-731
  - reduction of, associated with adjuvant chemotherapy, 736-737
  - trastuzumab-associated, 735-736
- Cardiomyopathy, following systemic chemotherapy, 732
- Cardioprotectant agents, 737
- Carotenoid, 86-87
- Caspase-3, 428
- Caspase-9, 428
- CAV chemotherapy regimen
  - in limited small cell lung cancer, 21
  - in small cell lung cancer, 11
  - topotecan *v*, 73, 74
- CC-5013, 309-311
- CCNU, in dose intensity trial, 13
- CD5, 203
- CD10, 203
- CD16, 426
- CD20, 133, 250, 425, 429
  - expression of, and complement-dependent cytotoxicity, 427
  - in lymphoproliferative disorders, 203
- CD20 antigen, 483
- CD22, 422
  - characterization of, 253
  - expression of, during B-lymphocyte development, 254
  - function of, 254-255
  - in immunotoxin strategy, 461
  - as lymphoma immunotherapy target, 458-459
  - tissue distribution of, 253
- CD22 alpha, 254
- CD22 beta, 254
- CD23, 203
- CD32, 426
- CD33, 422, 430
- CD34, 263
- CD38, 203
- CD45, 422
- CD52, 250
  - expression of, in B-lineage lymphoid malignancies, 498-499
- CD52 antigen, 429
- CD55, 426-427
- CD59, 426-427
- CD64, 426
- Cell death, Bcl-2 antisense and, 301
- Cell morphology, in lymphoproliferative disorders, 202-203
- Carbopend block, 597
- Chemoradiation
  - duration of, 33-34
  - early, 28-29
  - fractionation in, 32-33
  - induction, in small cell lung cancer, 51-52
  - radiotherapy dose in, 32-33
  - sequential, 29-31
- Chemoradiation package, 33-34
- Chemotherapy
  - ACE regimen of, 14-15
  - adjuvant, in small cell lung cancer, 49-50
  - benefits of, *v* second cancer risk, 746
  - cisplatin, etoposide consolidation of, 11
  - CODE regimen of, 11-12
  - cognitive effects following, 751
  - combination, in small cell lung cancer, 74, 75
  - as consolidation therapy, 442
  - in diffuse large cell lymphoma, 448-453
  - dose dense, in small cell lung cancer, 14-15
  - dose intensity of, 12-14
  - dose-intensified, adjuvant, leukemia following, 744
  - early modality integration *v* sequential delivery of, 28, 29-31
  - escalating, with autologous bone marrow transplant, 15
  - EVI regimen of, 15
  - Goldie and Coldman hypothesis of, 11
  - high-dose, with stem cell support, 286-289, 291-295
  - leukemia following, 744
  - in low-grade lymphoma, 441
  - maintenance, clinical trials of, 10
  - mechanisms of, impacting cognitive function, 754-755
  - neoadjuvant, in small cell lung cancer, 50-51
  - neuropsychological impact of, 750-753
  - ovarian failure due to, 764-767
  - peripheral blood stem cell support with, 15
  - resistance to, chemoradiation and, 28
  - with rituximab, 440-442
  - second cancers following, 743-745
  - short intensive weekly, 11-12
  - in small cell lung cancer, 9-11
  - systemic, long-term side effects of, 731-732
  - V-ICE regimen of, 14-15
  - in Waldenstrom's macroglobulinemia, 208-209
- Chest radiography, colorectal cancer and, 351-352
- Chlorambucil, 121
  - in Waldenstrom's macroglobulinemia, 236-238
- 2-Chlorordeoxyadenosine, *see* Cladribine
- Choline, 625
- Chromosomal abnormalities
  - in small cell lung cancer, 57-58
  - in Waldenstrom's macroglobulinemia, 143
- Chromosome 3p, in small cell lung cancer, 57
- Chronic lymphocytic leukemia, therapy of, infections and, 497-498
- Cigarette smoking
  - lung cancer and, 94-95
  - nicotine dependence and, 97
  - nicotine replacement therapy and, 97-99
  - tobacco dependence and, 96
- Ciglitazone, 309-311
- Cisplatin
  - in dose-intensity trial, 13

- Cisplatin (*Continued*)  
 in small cell lung cancer, 11, 15-16, 21
- Cisplatin, etoposide regimen, 11
- Cisplatin, ifosfamide, irinotecan regimen, 75
- Cisplatin, ifosfamide, paclitaxel regimen, 75
- Cisplatin, irinotecan regimen, 75
- Cisplatin, paclitaxel, etoposide regimen, 21-22
- Cisplatin, topotecan regimen, 75
- Cladribine, 121, 122  
 re-treatment sensitivity with, 245  
 toxicity of, 245  
 in Waldenstrom's macroglobulinemia, 208-209, 237, 243-247
- Clarithromycin, 123  
 in combination therapy, 266-267  
 toxicity of, 272  
 in Waldenstrom's macroglobulinemia, 270-273
- Classification accuracy, 573-574
- Clinical trial, two-arm phase III, sample size for, 35
- Clodronate, oral, 769
- Clonidine, 98, 100, 782, 783
- CLOX, 757
- CNS lymphoma, rituximab in, 452-453
- CODE chemotherapy regimen, in small cell lung cancer, 11-12
- Cognitive behavioral stress management, 759
- Cognitive dysfunction, following systemic chemotherapy, 732
- Cognitive function  
 chemotherapy mechanisms impacting on, 754-755  
 following adjuvant therapy, 749-750  
 hormonal influences on, 756-757  
 ongoing longitudinal trials studying, 753-754
- CogState, 757-758
- Cold agglutinin(s), 318-323  
 activity of, 137
- Colonoscopy, colorectal cancer recurrence and, 352
- Colorectal cancer  
 follow-up of, current practice patterns in, 356  
 incidence of, 349  
 oncology organization follow-up recommendations in, 356-357
- Colorectal cancer recurrence  
 carcinoembryonic antigen testing and, 351  
 chemotherapy in, 350  
 chest radiography and, 351-352  
 colonoscopy and, 352  
 liver ultrasound and, 352  
 positron emission tomography with 18F-fluorodeoxyglucose and, 352-353  
 routine physical examination and, 350-351  
 surgery in, 349-350
- Colorectal cancer surveillance  
 cost-benefit analysis of, 355  
 quality of life and, 355-356  
 randomized clinical trials of, 353-355
- Combined modality therapy  
 duration of, 33-34  
 early modality integration v sequential delivery in, 28, 29-31  
 in limited-stage small cell lung cancer, 26-28
- Complement-dependent cytotoxicity, 425, 467-468
- CD20 expression and, 427
- rituximab and, 426-427
- Complementary-determining region, 424
- Computed tomography  
 axial, in prostate cancer, 618  
 in breast cancer surveillance, 342-343  
 contrast-enhanced, in prostate cancer, 618  
 following ovarian cancer, 403-406  
 in prostate cancer, 622-623  
 recurrent prostate cancer and, 617-618
- Concentration, following chemotherapy, 750
- Concordance index, 573
- Congestive heart failure, following systemic chemotherapy, 732
- Conjugated equine estrogens, 782
- Conjugated monoclonal antibody, definition of, 424
- Consensus Panel I, 108
- Consensus Panel II, 108
- Consensus Panel III, 108
- Consensus Panel IV, 108-109
- Consolidation therapy, chemotherapy followed by rituximab as, 442
- Contrast-enhanced Doppler ultrasound, in prostate cancer, 590
- Coordination, following chemotherapy, 750
- Cost-benefit analysis, of colorectal cancer surveillance, 355
- CPT-11, in small cell lung cancer, 16-17
- Cranial irradiation  
 clinical trials of, with neuropsychological assessment, 42  
 efficacy of, 42-44  
 future directions in, 45  
 neurocognitive outcomes with, 41-42  
 randomized trials of, 43, 44  
 shielding in, 45  
 in small cell lung cancer, 38-40  
 technical recommendations for, 44-45  
 toxicity of, 40-41
- Cross-validation, 574
- Crush artifact, 5
- Cryoglobulinemia, 124
- CTLA-4, 656
- CWR22 human xenograft, 643
- Cyclophosphamide  
 adjuvant, leukemia following, 744  
 cardiotoxicity of, 735  
 cognitive effects following, 751  
 in dose intensity trial, 13  
 neurotoxicity due to, 755  
 ovarian failure due to, 765-766  
 second cancer following, 743
- Cyclophosphamide, doxorubicin regimen, cardiac effects of, 731
- Cyclophosphamide, fluorouracil, epirubicin regimen, cardiac effects of, 731
- Cyclophosphamide, methotrexate, fluorouracil regimen, cardiac toxicity of, 732-733
- Cyclophosphamide, thiotepa, carboplatin regimen, cardiac effects of, 731
- CYP-19, 769-770
- Cytokine(s)  
 chemotherapy neurotoxic effects and, 754-755  
 as prostate cancer immunotherapy, 656
- Cytomorphology, definition of, 112
- Cytopenia, in Waldenstrom's macroglobulinemia, 218

- Cytoskeletal pathway, in lung cancer, 64-65  
Cytotoxins, peptide class I, in hematologic neoplasm immunotoxins, 548
- Daclizumab, 514  
Data-splitting, 574  
Daunorubicin, relative cardiotoxicity of, 733  
Dendritic cell, 661, 662  
    in immunity, 306-307  
    as tumor vaccine, 649, 651  
Dendritic cell-mediated immunization, 305-307  
Dexamethasone, 123  
    in combination therapy, 266-267, 270-273  
    neurotoxicity due to, 755  
    toxicity of, 272  
    in Waldenström's macroglobulinemia, 270-273  
Dexrazoxane, 737  
Diet, lung cancer and, 87-89  
Dietary fiber, 793-794  
Differentiation agent, 688  
    development of, obstacles to, 694-695  
    potential role of, 689  
Diffuse large cell lymphoma, rituximab in, with chemotherapy, 448-453  
Digital rectal examination, in prostate cancer, 616-617  
Digitally reconstructed radiograph, 603  
Dihydroethidine, 428  
Dinitrofluorobenzene, hapten, 660  
Discrimination, definition of, 572-573  
DNA vaccination, 662-663  
Docetaxel, 73  
    in small cell lung cancer, 16-17  
Dose-volume histogram, 599, 601  
Doxil, 736-737  
Doxorubicin  
    cardiac toxicity following, 732-733  
    cognitive effects following, 751  
    in dose intensity trial, 13  
    neurotoxicity due to, 755  
    relative cardiotoxicity of, 733  
    scheduling of, and cardiotoxicity, 736  
    second cancer following, 743  
Doxorubicin, cyclophosphamide regimen, cardiac effects of, 731  
Doxorubicin, paclitaxel regimen, in small cell lung cancer, 75  
Doxorubicin, radiotherapy regimen, cardiac effects of, 731  
DT388GMCSF, 551  
Dutcher bodies, in Waldenström's macroglobulinemia, 183
- E-cadherin, 589  
E3 ligase inhibitor, 278-280  
E99, 668-670  
Effector cell-dependent cytotoxicity, 467-468  
Electropherogram, GeneScan analysis, of PCR products, 167  
Electrocardiographic changes, following systemic chemotherapy, 732  
Endometrial biopsy, in screening, 344  
Endomyocardial biopsy, in cardiotoxicity, 734  
Endothelin, 589  
    in prostate cancer, 678-680  
Endothelin axis, 677-678  
Endothelin receptor, clinical studies of, 680-684  
Epirubicin  
    adjuvant, cardiac effects of, 731  
    cognitive effects following, 751  
    leukemia following, 744  
    neurotoxicity due to, 755  
    relative cardiotoxicity of, 733  
Epirubicin, cyclophosphamide, fluorouracil regimen, cardiac effects of, 731  
Epratuzumab, 248-249, 444, 453-454, 459-461  
    clinical applications of, 255-256  
    efficacy of, 255  
    radiolabeled murine LL2 with, 459-460  
    rituximab with, 461  
    unlabeled, clinical studies with, 460-461  
    Yttrium 90-, 459-460  
Erythropoietin, 759  
Estradiol level, 779  
Estradiol vaginal ring, 782, 783  
Estramustine, oral, in prostate cancer, 565  
Estramustine, etoposide regimen, in prostate cancer, 565  
Estramustine, vinblastine regimen, in prostate cancer, 565  
Estrogen  
    breast cancer risk of, 777-778, 783  
    cognitive function and, 756-757  
    progesterin plus, and breast cancer, 778-780  
Estrogen deficiency, management of, 782  
    in breast cancer, 776-777  
Estrogen plus progesterin products, revised FDA labeling for, 780  
Estrone level, 779  
ET-1, 678-680  
Etoposide  
    in dose-intensity trial, 13  
    in palliative therapy, 15-16  
    in prostate cancer, 565  
    in small cell lung cancer, 11, 15-16, 21  
Etoposide, cisplatin regimen, in small cell lung cancer, 11  
Etoposide, estramustine regimen, in prostate cancer, 565  
Etoposide, irinotecan regimen, in small cell lung cancer, 75  
Etoposide, paclitaxel, cisplatin regimen, in limited small cell lung cancer, 21-22  
European Society for Medical Oncology, recommendations of, in colorectal cancer recurrence, 356-357  
EVI chemotherapy regimen, in small cell lung cancer, 15  
Evidence-based follow-up, levels of, for guideline-making, 363  
Executive functioning, following chemotherapy, 750  
EXIT25, 757  
Expanded prostate cancer index composite, 582  
Expressed sequence tags, 636  
External-beam radiotherapy, 576-577  
    complications of, 582  
    contraindications to, 580  
    conventional techniques in, 597-598  
    disadvantages of, 581  
    four-field approach in, 597  
    in localized prostate cancer, 596-597  
    rotational technique in, 597-598



- Familial Waldenstrom's macroglobulinemia  
 characteristics of, 146-147  
 epidemiology of, 146  
 immunologic characterization in, 147-150
- FHIT gene, in small cell lung cancer, 57-58
- Fibroblast growth factor, basic, in prostate cancer, 589
- Fludarabine, 121, 122  
 stem cell collection and, 287  
 toxicity of, 241  
 in Waldenstrom's macroglobulinemia, 221-224, 237, 239-241
- Fluorouracil  
 adjuvant, leukemia following, 744  
 cognitive effects following, 751  
 myelodysplasia following, 744  
 neurotoxicity due to, 755  
 second cancer following, 743
- Fluorouracil, cyclophosphamide, methotrexate regimen,  
 cardiac toxicity of, 732-733
- Fluorouracil, epirubicin, cyclophosphamide regimen, cardiac  
 effects of, 731
- Fluoxetine, 782, 784
- Follicular lymphoma, rituximab in, 436-437
- Forward side scatter, in apoptosis, 427
- Fragile histidine triad gene, in small cell lung cancer, 57-58
- Fruits, potentially anticarcinogenic substances in, 88
- Fucosyl GM1, 82, 83
- Fulvestrant, 768-769, 777
- Functional Assessment of Cancer Therapy-Cog, 758
- G-protein-coupled receptor, in lung cancer, 62
- G3139, see Oblimersen sodium
- Gabapentin, 782, 784
- Gastrin-releasing peptide, in small cell lung cancer, 75
- GD3, 82-83
- Geldanamycin, 310, 710
- Gemcitabine, 73  
 in small cell lung cancer, 17
- Gemcitabine, paclitaxel regimen, in small cell lung cancer,  
 75
- Gemtuzumab ozogamicin, 422, 502-503  
 with chemotherapy, 505-506  
 definition of, 430  
 initial trials of, 503  
 mechanisms of resistance to, 505  
 in secondary acute myeloid leukemia, 506-507  
 stem cell transplant strategies and, 506  
 toxicities of, 504-505
- Gene expression, highest ranked differential, in metastatic  
 prostate cancer, 644-645
- Gene expression analysis  
 of androgen ablation-resistant prostate cancer, 642-643  
 of androgen response pathway, 642-643  
 data analysis and, 638  
 microarray-based, steps in, 637  
 of neoplastic prostate transformation, 639-641  
 and prognostic features, 641  
 of prostate cancer, 638-647  
 of prostate cancer progression, 641-642  
 technical aspects of, 636  
 tissue heterogeneity and, 637-638
- Gene expression analysis (*Continued*)  
 transcript profiling methods in, 636
- Generalizability, 572
- GeneScan analysis, Electropherogram, 167
- Genetic findings, in lymphoproliferative disorders, 204
- Germ cell tumor(s)  
 follow-up recommendations for, 385-387  
 incidence of, 382  
 long-term therapy effects of, follow-up of, 388-389  
 treated, follow-up studies for, 387-388  
 tumor-node-metastasis stages of, 383
- Germinal center, 136
- Ginkgo biloba, 759
- Ginseng, 759
- Gleason grade, 574
- Gleason sum, 574
- Globo H hexasaccharide, 655
- Goldie and Coldman hypothesis, 11
- Goserelin, 777-778
- Graft-versus-host disease  
 acute, prevention of, 511  
 chronic, 515-516  
 monoclonal antibody therapy in, 509-511  
 primary treatment of, 513  
 steroid-resistant, 513-514
- Graft-versus-lymphoma effect, 289
- Graft-versus-myeloma effect, 289
- Graft-versus-Waldenstrom's macroglobulinemia effect, 295
- Granulocyte-macrophage colony-stimulating factor, 660  
 in dose-dense chemotherapy regimen, 14-15  
 rituximab with, 443
- Halotestin, adjuvant, leukemia following, 744
- HAS1, 165-166
- HAS2, 166-167
- HAS3, 166
- Healthy lifestyle, for women, 769
- Heat shock factor 1, 712
- Heat shock protein, 662  
 in prostate cancer, 710-711
- Heat shock protein 90, 710-711  
 as cancer therapy target, 711-713  
 molecular chaperone, inhibitors of, 309-311
- Hemoglobin  
 levels of, 207, 209  
 as prognostic factor, 214-215
- Hepatocyte growth factor, in lung cancer, 60-62
- Hepsin, 589
- HER2, 735
- Herbal therapy, of estrogen deficiency, 784
- High Sensitivity Cognitive Screen, 752
- Histone, 692-693
- Histone deacetylase inhibitor, 309-311
- HIV-associated large cell lymphoma, rituximab in, 452
- HLA-DR, 422
- Hodgkin's disease, lymphocyte-predominant, 440
- Hodgkin's lymphoma  
 follow-up cost in, 379  
 relapse characteristics in, 377  
 relapse detection in, 377-378  
 relapse in, 376



- Hodgkin's lymphoma (*Continued*)  
 relapse symptoms in, 377  
 secondary, 378  
 surveillance in, evidence-based recommendations for, 379-380  
 treatment-related complication follow-up in, 378-379
- Hopkins Symptom Checklist-25, 751
- Hormonal therapy  
 cognitive function and, 756-757  
 second cancers following, 745-746
- Hormone-replacement therapy, breast cancer and, 822-823
- Hu1D10, 454, 470-471
- Human epidermal growth factor receptor-2, 735
- Human glandular kallikrein-2, 589
- Human leukocyte antigen class II antibodies, 465-466
- Human tumor control probability curve, 599
- Humanized LL2, 459-461
- Hyaluronan, in Waldenstrom's macroglobulinemia, 165-167
- Hyaluronan synthases, 165
- Hyperviscosity syndrome, 124, 236
- I Can Cope, 809-810
- Ibritumomab, 444
- Idarubicin, relative cardiotoxicity of, 733
- IDEC-114, 454
- Ifosfamide  
 in chemotherapy combination regimens, 18  
 in small cell lung cancer, 17
- Ifosfamide, irinotecan, cisplatin regimen, 75
- Ifosfamide, paclitaxel, cisplatin regimen, 75
- IgG molecule, composition of, 424
- IgRFB4-IgA, 551
- Imatinib, 81
- Immune modulatory drug, 275-277
- Immunofixation, 129
- Immunofluorescence assay, 669
- Immunoglobulin, monoclonal, with antibody activity, 318-323
- Immunoglobulin H region, switch translocations at, 143
- Immunoglobulin M  
 amyloidosis with, 325-327  
 levels of, in Waldenstrom's macroglobulinemia, 127-128, 207, 209  
 quantification of, 129  
 secretion of, 111
- Immunoglobulin M monoclonal gammopathy  
 asymptomatic, 172  
 clinical characteristics of, 173  
 malignant transformation risk for, 174-175
- Immunoglobulin M monoclonal gammopathy of undetermined significance  
 initial characteristics of, 179  
 long-term follow-up of, 169-171  
 malignant transformation risk for, 179-180
- Immunoglobulin M monoclonal protein, concentration of, in Waldenstrom's macroglobulinemia, 197
- Immunoglobulin M myeloma, 198-199
- Immunophenotypic study(ies)  
 in lymphoproliferative disorders, 203-204  
 in Waldenstrom's macroglobulinemia, 185
- Immunotherapy, clinical trials of, in prostate cancer, 652
- Immunotoxin strategy, CD22 in, 461
- Immunotoxin therapy, in small cell lung cancer, 75-76
- Immunotoxin(s)  
 clinical results with, 550-553  
 clinical trials of, 553-554  
 efficacy of, 550-551  
 immune responses of, 552  
 in vitro potency of, for hematologic malignancies, 546-547  
 pharmacokinetics of, 551-552  
 synthesis of, 545-550  
 toxicities of, 552-553
- Indium 111-capromab pendetide, in prostate cancer, 622
- Infertility, following systemic chemotherapy, 732
- Inflizimab, 515
- Insulin-like growth factor, in prostate cancer, 589
- Insulin-like growth factor I, in lung cancer, 60
- Intensity-modulated radiotherapy, 597, 602  
 androgen deprivation and, 611-612  
 characterization of, 600  
 computer-automated optimization in, 603-604  
 delivery of, 604-605  
 neoadjuvant androgen deprivation and, 611  
 rectal and urinary toxicity in, 606  
 template of, for prostate treatment plan, 604
- Interferon-alpha, rituximab with, 442-443
- Interleukin-2, 453  
 rituximab with, 443
- Interleukin-12, 453  
 rituximab with, 443
- International Prostate Symptom Score, 396
- Iodine 111-tositumomab, 444
- Iodine 131-radiolabeled Lym-1, 454
- Iodine 131-tositumomab, 453, 538-539  
 clinical trials of, 539-540  
 toxicity of, 540-541
- Irinotecan  
 in chemotherapy combination regimens, 20-21  
 in small cell lung cancer, 73
- Irinotecan, cisplatin regimen, 75
- Irinotecan, etoposide regimen, 75
- Irinotecan, ifosfamide, cisplatin regimen, 75
- J-415, 668-670, 672
- J-533, 668-670
- J-591, 654, 668-672  
 in prostate cancer, 622  
 radiolabeled human, phase I trials of, 672-673  
 in solid tumor malignancies, 675-676
- Jackknife method, 574
- Jun N-terminal kinase inhibitors, 277-278  
 activation of, 276  
 signaling cascade involving, 278  
 uses of, 278
- Ki-67, 589
- L-Pam, second cancer following, 743
- L-phenylalanine mustard, second cancer following, 743
- Large cell lymphoma, relapsed, rituximab in, 450
- Large cell neuroendocrine cancer, 6
- Latency period, 740

- Left ventricular ejection fraction
  - evaluation of, guidelines for, 734
  - following chemotherapy, 734-735
- Letrozole, 769-770
- Leukemia, following adjuvant chemotherapy, 744-745
- Liposomal anthracycline, 736-737
- Liver ultrasound, colorectal cancer recurrence and, 352
- LMB2, 551
- Lung cancer
  - American Society of Clinical Oncology follow-up
    - guidelines in, 363, 364
  - diet and, 87-89
  - follow-up guidelines in, 361-364
  - follow-up in, current practice of, 364-367
  - follow-up studies in, 365
  - following breast cancer radiotherapy, 743
  - incidence of, 86
  - intense follow-up in, reasons for, 366
  - smoking and, 86, 94-95
  - smoking cessation and, 95-96
- Lung cancer surveillance
  - non-small cell, follow-up guidelines in, 361-363
  - patient concerns about, 362
  - physician concerns about, 362
  - small cell, follow-up in, 363-364
- Lutein, chemical structure of, 87
- Lycopene, chemical structure of, 87
- Lym-1, 470
- Lym-1 antibody, 454
- Lymph node metastasis, in prostate cancer, 626
- Lymphadenopathy, 130
- Lymphedema, 820
- Lymphoma
  - CNS, rituximab in, 452-453
  - diffuse large cell, 448-453
  - follicular, 436-437
  - HIV-associated large cell, 452
  - low-grade, rituximab dosing in, 438
  - lymphoplasmacytoid, 439-440
  - malt, 440
  - small lymphocytic, 439
- Lymphoma
  - classification of, 375
  - curability of, 375-376
  - follow-up cost in, 379
  - relapse characteristics in, 377
  - relapse detection in, 377-378
  - relapse symptoms in, 377
  - response assessment in, 376
  - secondary, 378
  - surveillance in, evidence-based recommendations for, 379-380
  - treatment-related complication follow-up in, 378-379
- Lymphoplasmacytic lymphoma, 108
  - definition of, 111-112
  - phenotypic profiles in, without M-component, 190
- Lymphoplasmacytoid lymphoma, rituximab in, 439-440
- Lymphoproliferative disorder
  - low-grade B-cell, *v* Waldenstrom's macroglobulinemia, 202-204
  - with Waldenstrom's macroglobulinemia features, 202
- Magnetic resonance imaging
  - bone marrow survey with, 629
  - in breast cancer surveillance, 342-343
  - cognitive function and, 758
  - following ovarian cancer, 404-406
  - in prostate cancer, 590, 618-620
- Magnetic resonance spectroscopy, in prostate cancer, 590, 620-621
- Major histocompatibility complex class II antibodies,
  - mechanisms of action of, 466-468
- Malt lymphoma, characterization of, 440
- Mammography, screening, 338-339
- Marimstat, 81
- Mastectomy, 802
- Matrix metalloproteinase inhibitor, in small cell lung cancer, 80-81
- Mcl-1 to Bax ratio, 428
- Medroxyprogesterone acetate, 782
- Megestrol acetate, 781-782
  - breast cancer risk of, 783
- Melanoma
  - follow-up in, 372-373
  - incidence of, 369-370
  - natural history of, 370
  - prognosis in, 370
  - recurrence detection in, 370-372
  - second primary, risk for, 372
- Melphalan, high-dose, in Waldenstrom's macroglobulinemia, 282-284
- Memory, following chemotherapy, 750
- Menopause
  - breast cancer relapse and, 339
  - cognitive function and, 756-757
  - early, following systemic chemotherapy, 732
- Metastasis
  - bone resorption in, 717
  - osteoblastic, 719
  - in prostate cancer, 679
  - reduced, chemoradiation and, 28
- Methotrexate
  - adjuvant, leukemia following, 744
  - cognitive effects following, 751
  - in dose intensity trial, 13
  - neurotoxicity due to, 755
  - second cancer following, 743
- Methotrexate, cyclophosphamide, fluorouracil regimen,
  - cardiac toxicity of, 732-733
- Methylphenidate, 759
- Methylprednisolone, neurotoxicity due to, 755
- Microvessel density, in Waldenstrom's macroglobulinemia, 263
- Minimal disease monitoring, stem cell graft purging and, 520-522
- Mitogenesis, in prostate cancer, 678-679
- Mitoxantrone, relative cardiotoxicity of, 733
- Mitoxantrone, prednisone regimen, in prostate cancer, 565
- MLC leaf position, 602, 603
- Monoclonal antibody(ies)
  - conjugated, 424
  - in development, 453-454
  - radiolabeled, 522-524

- Monoclonal antibody(ies) (*Continued*)  
   to prostate-specific membrane antigen, 668-670  
   in small cell lung cancer, 75  
   unlabeled, in stem cell transplantation, 524-527
- Monoclonal antibody 2A11, in small cell lung cancer, 75
- Monoclonal antibody BEC2, 83
- Monoclonal antibody imaging, in prostate cancer, 622
- Monoclonal antibody N901, in small cell lung cancer, 75-76
- Monoclonal antibody therapy  
   antibody structure in, 458  
   for B-cell malignancies antigenic targets, 458  
   combination, 249, 251  
   for hematologic malignancies, 421-423  
   main advantage of, 424  
   target selection in, 457-458  
   in Waldenstrom's macroglobulinemia, 248-251
- Monoclonal gammopathy of undetermined significance, 111  
   classification of, 113  
   criteria for, 112  
   IgM, long-term follow-up of, 169-171
- Monoclonal immunoglobulin, with antibody activity, 318-323
- Morel score, 230
- Motor function, following chemotherapy, 750
- Mouse xenograft model, in Waldenstrom's macroglobulinemia, 313-316
- Mt-SP1, 589
- Multiple myeloma, response criteria for, and Waldenstrom's macroglobulinemia, 329-331
- MYC gene, in lung cancer, 58
- Mycophenolate mofetil, 510
- Myelodysplasia, following adjuvant chemotherapy, 744-745
- Myocardial infarction, following systemic chemotherapy, 732
- Myocarditis, following systemic chemotherapy, 732
- National Comprehensive Cancer Network, recommendations of, in colorectal cancer recurrence, 356-357
- Natural killer cell, 426, 467-468, 472
- Natural products, in estrogen deficiency management, 784
- Nephelometry, 129
- Neural cell adhesion molecule, in lung cancer, 63
- Neuroendocrine cancer, large cell, 6
- Neuroendocrine lung tumor, diagnosis criteria for, 7
- Neuropathy, 124
- Neuropsychiatric testing, 757-758
- Nicotine  
   dependence on, 97  
   novel treatments in, 100
- Nicotine gum, 98, 99
- Nicotine inhaler, 98, 99
- Nicotine nasal spray, 98, 99
- Nicotine patch, 97-98
- Nicotine polacrilex, 99
- Nicotine replacement therapy, 97-99  
   combination, 99
- Nicotine straw, 100
- Nicotine vaccine, 100
- NKH-1, in small cell lung cancer, 75
- Nomogram  
   brachytherapy calibration, 579  
   calibration of, 577, 578
- Nomogram (*Continued*)  
   definition of, 568  
   development of, 572-575  
   future of, 580-585  
   limitations of, 579-580  
   modeling considerations for, 574-575  
   Palm Pilot software for, 571  
   postoperative, for prostate cancer recurrence, 576  
   preoperative, calibration plot of, 573  
   for PSA recurrence, 578  
   treatment efficacy and, 578-579  
   usefulness of, 570-571
- Non-Hodgkin's lymphoma  
   follow-up cost in, 379  
   relapse characteristics in, 377  
   relapse detection in, 377-378  
   relapse in, 376-377  
   relapse symptoms in, 377  
   secondary, 378  
   surveillance in, evidence-based recommendations for, 379-380  
   treatment-related complication follow-up in, 378-379
- Non-small cell lung cancer, follow-up guidelines in, 361-363
- Nonseminoma  
   advanced, 384-385  
   chemotherapy-treated advanced, follow-up for, 386  
   early-stage, therapy for, 382-384  
   follow-up recommendations for, 385-387  
   stage I, 386  
   stage II, 385  
   stage III, 385  
   treatment of, 384
- Nortriptyline, 98, 100
- Notch receptor, in lung cancer, 62-63
- Nuclear factor kappa B, activation of, 161-163
- Nuclear-to-cytoplasmic ratio, high, 5
- Nucleosome, 692-693
- Obesity, breast cancer and, 789-792
- Oblimersen sodium, 297-299  
   clinical studies of, 301-302  
   phase I-II trial of, 302  
   preclinical activity of, 301  
   in Waldenstrom's macroglobulinemia, 297-299, 300-303
- Oligodeoxynucleotides, immunostimulatory CpG, 476-480
- One D10, 470-471
- ONTAK, 551
- Orchiectomy, in prostate cancer, 394-395
- Organomegaly, 130
- Osteoblast, 718
- Osteoclast, 718
- Osteogenesis, in prostate cancer, 679-680
- Osteolytic factor, 718
- Osteopenia, in breast cancer, 770-771
- Osteoporosis  
   managing, in breast cancer, 770-771  
   pathogenesis of, 764  
   risk factors for, 766
- Osteoporosis equation, 765
- Osteoprotegerin, 763

- Outcomes research, clinical end points in, of prostate cancer, 569
- Ovarian cancer  
   physical examination following, 401-402  
   radiologic studies following, 403-406  
   second-look surgery in, 406-408  
   survival in, 402  
   tumor markers following, 402-403
- Ovarian failure  
   bone loss and, 767  
   chemotherapy-induced, 764-767
- Overfitting, 572
- p13K pathway, in lung cancer, 63-64
- p27, 589
- p50, 163
- p53, 589  
   in lung cancer, 59
- p65, 163
- Paclitaxel  
   cardiotoxicity of, 735  
   in combination chemotherapy regimens, 18-19  
   neurotoxicity due to, 755  
   in small cell lung cancer, 16-17, 73
- Paclitaxel, carboplatin regimen, 75
- Paclitaxel, doxorubicin regimen, 75
- Paclitaxel, etoposide, cisplatin regimen, 21-22
- Paclitaxel, gemcitabine regimen, 75
- Paclitaxel, ifosfamide, cisplatin regimen, 75
- Pain, due to ET-1, in prostate cancer, 680
- Palliative therapy, in small cell lung cancer, 15-16
- Paraprotein, 323
- Paroxetine, 782, 784
- Paroxysmal nocturnal hemoglobinuria, 430
- Patients  
   intense lung cancer follow-up and, 366  
   lung cancer surveillance and, 362
- PAX-5 gene, 204
- Paxillin, 65
- PDK1, in lung cancer, 63-64
- Pericarditis  
   acute radiation-associated, 731  
   following systemic chemotherapy, 732
- Peripheral blood stem cell support, in small cell lung cancer chemotherapy, 15
- Peripheral blood stem cell transplantation  
   rituximab and, 450-451  
   in Waldenstrom's macroglobulinemia, 282-284, 291-295
- Peroxisome proliferator-activated receptor gamma ligands, 693-694  
   cancers and, 703  
   clinical data of, 705  
   liposarcoma and, 702-703  
   mechanisms of action of, 704-705  
   prostate cancer and, 703-704
- PET, see Positron emission tomography
- Phase II trial, of endothelin receptors, 681-684
- Physicians  
   intense lung cancer follow-up and, 366  
   lung cancer surveillance and, 362
- Pioglitazone, 694
- Planning target volume, 599, 601
- Plasma cell, in Waldenstrom's macroglobulinemia, 183
- Plasma cell disorders, angiogenesis in, 262
- Plasmacytoid lymphocyte, in Waldenstrom's macroglobulinemia, 183
- Plasmapheresis, 124
- Poly-adenosine diphosphate ribose polymerase, 428
- Polymorphonuclear neutrophils, 468, 472
- Positron emission tomography, 590  
   in breast cancer surveillance, 342-343  
   in cardiotoxicity, 734  
   cognitive function and, 758  
   colorectal cancer recurrence and, 352-353  
   following ovarian cancer, 405-406, 406  
   in limited small cell cancer, 21  
   in metastatic ovarian cancer, 407  
   in prostate cancer, 622-623, 625-626
- Post-transplant lymphoproliferative disease, rituximab in, 451-452
- Post-traumatic stress disorder, breast cancer and, 801
- Practice effect, 757
- Prednisone, mitoxantrone regimen, in prostate cancer, 565
- Premarin, 779-780
- Primates, in human leukocyte antigen class II antibody trials, 468-470
- Prinomastat, 81
- Profile of Mood States, 752
- Progesterone, cognitive function and, 756
- Progestin  
   breast cancer risk of, 783  
   estrogen plus, and breast cancer, 778-780  
   in vasomotor symptoms management, 781-782
- Progestin plus estrogen product, revised FDA labeling for, 780
- Prognostic factors, staging v, in Waldenstrom's macroglobulinemia, 214-215
- Prognostic scoring system, in Waldenstrom's macroglobulinemia, 230
- ProstaScint imaging, 622, 625, 628  
   lymph node metastases and, 626
- ProstaScint scan, 588, 668
- Prostasin, 589
- Prostate acid phosphatase, 652-653
- Prostate cancer  
   amphotropic phase of, 563-564  
   androgen ablation-resistant, 646-647  
   antigen ablation in, 565  
   bone-targeting therapies in, 565  
   classification of, 562  
   clinical end points in, 568-570  
   clonal expansion phase of, 564  
   computed tomography in, 617-618  
   digital rectal examination in, 616-617  
   disease progression in, 569-570  
   disease states in, 571  
   disease-free probability in, 569-570  
   disease-specific survival in, 569  
   follow-up options in, 397  
   follow-up recommendations in, 395-398  
   following hormone therapy, 709-710  
   heterotrophic phase of, 564-565

- Prostate cancer (*Continued*)  
immunotherapy trials in, 652  
incidence of, 567  
International Symptom Score in, 396  
localized, competing risk analysis in, 591  
locally recurrent, imaging detection of, 623-624  
management of, 587-588  
monoclonal antibody imaging in, 622  
natural course of, 390-391  
overall survival in, 569  
progression of, classification of, 563  
prostate specific antigen relapse in, 568-570  
radiation complications in, 393  
recurrence of, preoperative nomogram for, 568  
recurrence staging in, 394  
recurrent, 393-395  
routine health maintenance in, 398  
surgery complications in, 392-393  
surgical v radiotherapeutic complications in, 393  
therapy complications in, 582  
therapy contraindications in, 580  
therapy indications in, 580  
therapy of, quality of life following, 391-392  
transrectal sonography in, 617  
treatment options in, 567  
watchful waiting complications in, 391-392  
watchful waiting in, 581
- Prostate Intervention Versus Observation trial, 591
- Prostate intraepithelial neoplasia, 588
- Prostate specific antigen, relapse and, 568-570
- Prostate transcriptome, in prostate cancer, 638-639
- Prostate-specific antigen, 622, 649, 651-652, 655  
in prostate cancer, 616-617
- Prostate-specific antigen doubling time, 588, 650-651  
in prostate cancer therapy selection, 591-592
- Prostate-specific antigen testing, widespread use of, 590-591
- Prostate-specific membrane antigen, 588-589, 649, 653-654, 668  
in prostate cancer, 622, 662, 663
- Prostatectomy, radical, 575-576, 581, 582, 619
- Prostatic acid phosphatase, 649, 668
- Proteasome inhibition, in Waldenstrom's macroglobulinemia, 310
- Protein  
chaperone, 712  
heat-shock, 662
- Protein antigen vaccine, 661
- Protein kinase C- $\alpha$ , in lung cancer, 64
- Proteomic profiling, in Waldenstrom's macroglobulinemia v multiple myeloma, 156-158
- PS-341, 310
- PSA, *see* Prostate-specific antigen
- Psychomotor functioning, following chemotherapy, 750
- PTEN gene, 647
- Quality of life, 749  
colorectal cancer surveillance and, 355-356  
following prostate cancer therapy, 391-392  
Quality-of-life measures, following chemotherapy, 750
- R-CHOP regimen, 449-450
- R-EPOCH regimen, 449-450
- Radiation therapy  
adjuvant, in early breast cancer, 730-731  
of breast, second cancer following, 742  
cardiac effects of, 730-731  
second cancer related to, 741-743
- Radiation therapy, doxorubicin regimen, cardiac effects of, 731
- Radiation-associated pericarditis, following breast cancer therapy, 731
- Radiation-associated vascular injury, following breast cancer therapy, 731
- Radical prostatectomy, 575-576  
complications of, 582  
contraindications to, 580  
disadvantages of, 581  
magnetic resonance imaging in, 619
- Radical, 712
- Radiograph, digitally reconstructed, 603
- Radioimmunoconjugates, elements of, 532-534
- Radioimmunoscintigraphy  
with ProstaScint, 628  
in prostate cancer, 624-625
- Radioimmunotherapy  
incorporation of, in clinical practice, 541-542  
targets for, 531-532  
in Waldenstrom's macroglobulinemia, 258-260
- Radionuclide angiography, 734
- Radiotherapy  
androgen deprivation and, 609-612  
benefits of, v second cancer risk, 746  
complications of, 393  
dosing of, in small cell lung cancer, 32-33  
early modality integration v sequential delivery of, 28  
early v delayed, clinical trials of, 30  
external-beam, *see* External-beam radiotherapy  
future direction of, in small cell lung cancer, 34-35  
intensity-modulated, *see* Intensity-modulated radiotherapy  
lung cancer following, 743  
PET chemotherapy plus, 22  
resistance to, chemoradiation and, 28  
sequential, 29-31  
three-dimensional conformal, 577  
volume of, 31-32
- Radiotracer, in prostate cancer, 625-626
- Raloxifene, 767-768  
bone mineral density and, 768
- RAR-B gene, in small cell lung cancer, 58
- RB gene, in lung cancer, 59-60
- Reactive oxygen species, 427
- Reactive oxygen species pathway, in lung cancer, 65-67
- REAL classification, of Waldenstrom's macroglobulinemia, 107-108
- Receiver operating characteristic curve, 572-573
- Receptor activator nuclear factor-kappa B ligand, 763
- Replacement mutation, 138
- Retinoic acid receptor, beta form of, 58
- Retinoid(s)  
in prostate cancer, 689-691  
trials of, 690

- Retinoid X receptor, 698  
 REVIMID, 276-277  
 Revised European and American Lymphoma classification, of  
   Waldenstrom's macroglobulinemia, 107-108  
 RHAMM, intracellular, 165, 166  
 Rheumatoid factor, 318-323  
 Risedronate, oral, 769  
 Risk-benefit analysis, of second cancer risk v adjuvant  
   therapy, 746  
 Rituximab, 121, 122, 124, 238, 248-249, 256, 307, 421, 424,  
   457-458  
   additional dosing of, 437-439  
   antibody dependent-cell mediated cytotoxicity and, 425-426  
   apoptosis and, 428-429  
   with chemotherapy, 440-441, 487  
   in CNS lymphomas, 452-453  
   in combination therapy, 486-487  
   complement-dependent cytotoxicity and, 426-427  
   as consolidation therapy, 442  
   with cytokines, 453  
   definition of, 425  
   in diffuse large cell lymphoma, 448-453  
   dimerization of, 429  
   dose-intensive schedules of, 486  
   dosing of, 438  
   epratuzumab with, 461  
   following chemotherapy, 441-442  
   granulocyte-macrophage colony stimulating factor with,  
     443  
   in HIV-associated large cell lymphoma, 452  
   infusion toxicity with, 489-490  
   interferon-alpha with, 442-443  
   interleukin-12 with, 443  
   interleukin-2 with, 443  
   in low-grade lymphoma, 441  
   in lymphoplasmacytoid lymphoma, 439-440  
   mechanisms of action of, 425, 484  
   mechanisms of resistance to, 429  
   with monoclonal antibodies, 487  
   new approaches with, 453  
   peripheral blood stem cell transplantation and, 450-451  
   in post-transplant lymphoproliferative disease, 451-452  
   prophylaxis against, toxicity with, 489  
   in purging, 282-284  
   in relapsed large cell lymphoma, 450  
   as single agent, 434-435  
   in small lymphocytic lymphoma, 439  
   stepped up dosing of, 489  
   toxicity of, 487-488  
   trials of, in follicular lymphoma, 436-437  
   in Waldenstrom's macroglobulinemia, 440  
   weekly, in B-chronic lymphocytic leukemia, 484-486  
 Rodents, in human leukocyte antigen class II antibody trials,  
   468-469  
 Rosiglitazone, 695  
 Rosiglitazone, 309-311  
  
 Salt and pepper chromatin pattern, 5  
 Sarafotoxin, 680  
 Sarcoma  
   following breast cancer radiotherapy, 742  
   Sarcoma (*Continued*)  
     incidence of, 413-414  
     recurrence patterns in, 414  
     surveillance following, 414-415  
 Screening  
   for breast cancer relapse, 340  
   endometrial biopsy in, 344  
   mammography, 338-339  
   for therapy-related complications, of breast cancer, 344  
 Second cancer  
   adjuvant therapy benefits v, 746  
   following adjuvant chemotherapy, 743-745  
   following breast cancer radiotherapy, 742  
   following hormone therapy, 745-746  
   following systemic chemotherapy, 732  
   treatment-related, 740-741  
 Selective cytokine inhibitory drugs, 277  
 Selenium, Vitamin E, Chemoprevention Trial, 563-564  
 Self protein, 649  
 Seminoma  
   advanced, 384  
   early-stage, therapy for, 382  
   follow-up recommendations for, 385-387  
   radiation-treated stage I, follow-up for, 386  
   treated, follow-up studies for, 387-388  
   treatment of, 384  
 Serial analysis of gene expression, 636  
 Serotherapy  
   combination, 249, 251  
   in Waldenstrom's macroglobulinemia, 248-251  
 Seven E11, 668-670, 672  
 Seventeen AAG, 709-714  
 Side scatter, in apoptosis, 427  
 Silent mutation, 138  
 Single-photon emission computed tomography  
   coronal, 623  
   indium 111-antimyosin, in cardiotoxicity, 734  
   in prostate cancer, 622, 627-630  
 Small cell lung cancer  
   ACE chemotherapy regimen in, 14-15  
   antigens in, 82  
   autologous bone marrow transplant in, 15  
   brain metastases in, 38  
   chemotherapy dosing intensity in, 12-14  
   chemotherapy duration in, 9  
   chemotherapy failure in, surgery following, 52-53  
   chemotherapy in, 9  
   chemotherapy trials in, 10  
   chromosomal abnormalities in, 57-58  
   cisplatin, etoposide consolidation therapy in, 11  
   CODE chemotherapy regimen in, 11-12  
   combination chemotherapy in, 74, 75  
   dose-dense chemotherapy in, 14-15  
   EVI chemotherapy regimen in, 15  
   follow-up in, 363-364  
   Goldie and Coldman chemotherapy hypothesis in, 11  
   growth factor abnormalities in, 60  
   immunotoxin therapy in, 75-76  
   incidence of, 9  
   maintenance chemotherapy in, 9-11  
   maintenance chemotherapy trials in, 10

- Small cell lung cancer (*Continued*)
- matrix metalloproteinase inhibitor in, 80-81
  - minimal residual disease detection in, 79-80
  - monoclonal antibody therapy in, 75
  - neoadjuvant chemotherapy in, 50-51
  - optimal surgical approach in, 54
  - palliative therapy in, 15-16
  - pathology of, 4-7
  - peripheral blood stem cell support in, 15
  - PET chemotherapy regimen in, 21-22
  - potential surgical candidates in, 53-54
  - preoperative assessment in, 48
  - primary, 3
  - prognostic factors in, 72
  - radiotherapy dosing in, 32-33
  - radiotherapy plus PET regimen in, 22
  - recurrent, prognostic factors in, 72
  - short intensive weekly chemotherapy in, 11-12
  - single-agent therapy in, 72-74
  - surgery alone in, 48-49
  - surgery with adjuvant chemotherapy in, 49-50
  - surgical therapy of, 47-48
  - thoracic radiotherapy plus chemotherapy in, 26-27
  - tyrosine kinase inhibitor in, 81-82
  - V-ICE chemotherapy regimen in, 14-15
  - vaccination therapy in, 82-83
  - WHO classification of, 3-4
- Small lymphocytic lymphoma, rituximab in, 439
- Smoking
- cessation of, approach to, 96-100
  - lung cancer and, 86, 94-95
  - nicotine addiction and, 97
  - nicotine replacement therapy and, 97-99
  - tobacco dependence and, 96
- Smoldering Waldenstrom's macroglobulinemia, 117
- chlorambucil in, 236-238
  - clinical features of, 232
  - definition of, 231
  - natural history of, 233-234
  - prognostic factors for, 233
- Soft-tissue sarcoma
- incidence of, 413-414
  - recurrence patterns in, 414
  - surveillance following, 414-415
- Somatic mutation, 138
- Sonography, transrectal, and recurrent prostate cancer, 617
- Spatial functioning, following chemotherapy, 750
- SPECT, *see* Single-photon emission computed tomography
- Splenectomy, in Waldenstrom's macroglobulinemia, 124-125
- Steel factor, in lung cancer, 60
- Stem cell graft purging, minimal disease monitoring and, 520-522
- Stem cell transplantation
- allogeneic, 288, 294-295
  - autologous, 286-287, 291-295
  - chemoimmunotherapy combinations and, 527-528
  - stem cell collection problems for, 287
  - unlabeled monoclonal antibodies and, 524-527
  - in Waldenstrom's macroglobulinemia, 282-284, 286-289
- Step-and-shoot mode, 600
- STIR technique, 629
- SU5416, 60
- Suberoylanilide hydroxamic acid, 309-311, 693
- Surgery
- breast-conserving, 802
  - complications of, in prostate cancer, 392-393
  - following chemotherapy failure, in small cell lung cancer, 52-53
  - following neoadjuvant chemotherapy, in small cell lung cancer, 50-51
  - second-look, in ovarian cancer, 406-408
  - in small cell lung cancer, 47-48
- Surveillance, post-treatment, in curable malignancy, 337
- Survival
- definition of, in prostate cancer, 569
  - disease-specific, 569
  - in Waldenstrom's macroglobulinemia, 209, 212, 213-214
- TAG-72, 654-655
- Tamoxifen, 767-768
- bone mineral density and, 768
  - in early-stage breast cancer, 777-778
  - neurotoxicity due to, 755
  - second cancer following, 743
- Telomerase, 654
- in small cell lung cancer, 58
- Teniposide, in small cell lung cancer, 72-73
- TERT, 654
- Thalidomide, 123
- in combination therapy, 266-267
  - immunomodulatory derivatives of, 310-311
  - side effects of, 267
  - as single-agent therapy, 265-266
  - toxicity of, 272
  - in Waldenstrom's macroglobulinemia, 270-273
- Thiazolidinediones, 311
- Thiotepa
- adjuvant, leukemia following, 744
  - cognitive effects following, 751
- Thiotepa, cyclophosphamide, carboplatin regimen, cardiac effects of, 731
- Three-dimensional conformal radiotherapy
- biological basis of, 599-600
  - first-generation, computer-aided planning of, 601-603
  - intensity-modulated radiotherapy dose escalation study and, 605
  - in localized prostate cancer, 596-597
  - neoadjuvant androgen deprivation and, 611
  - in prostate cancer, 598-600
  - toxicity of, and intensity-modulated radiotherapy, 605-606
- Thrombosis, following systemic chemotherapy, 732
- Tissue biomarker, in prostate cancer, 589-590
- TLC D-99, 736-737
- TMPrss2, 589
- Topotecan
- CAV regimen *v.*, 73, 74
  - in chemotherapy combination regimens, 19
  - oral *v.* intravenous, 74
  - in small cell lung cancer, 17-18, 72-73
- Topotecan, cisplatin regimen, in small cell lung cancer, 75
- Tositumomab, 429
- iodine 111-, 444



- Tositumomab, 429 (*Continued*)  
 iodine 131-, 453, 538-541
- Transcript profiling, methods of, 636
- Transforming growth factor-beta, in lung cancer, 62
- Transrectal sonography, and recurrent prostate cancer, 617
- Transvaginal ultrasound, screening with, 344
- Trastuzumab, cardiotoxicity associated with, 735-736
- Treatment package, 33-34
- Troglitazone, 695, 704
- Troponin I, in cardiotoxicity, 734-735
- Tumor, accelerated repopulation of, and chemoradiation, 28-29, 32
- Tumor marker, breast cancer stage and, 341
- Tumor progression, immune system failure in, 305-306
- Tumor vaccination, in Waldenstrom's macroglobulinemia, 307
- Tumor vaccine  
 allogeneic tumor cell, 660  
 autologous, 660  
 carbohydrate, 660-661  
 dendritic cell, 661  
 DNA, 662-663  
 heterologous prime-boost strategy, 664  
 keyhole limpet hemocyanin conjugate, 660-661  
 protein antigen, 661  
 recombinant viral, 663-664  
 trials of, in prostate cancer, 652  
 using prostate cancer antigen, 655-656
- Tumor-node-metastasis staging, in germ cell tumors, 383
- Tumor-specific immunization, in Waldenstrom's macroglobulinemia, 307
- Two A11  
 in lung cancer, 62  
 in small cell lung cancer, 75
- Tyrosine kinase inhibitor, in small cell lung cancer, 81-82
- Ubiquitin ligase proteasome system, 280
- Ubiquitin ligase reaction, 279
- Ultrasound  
 of liver, colorectal cancer recurrence and, 352  
 transvaginal, screening and, 344
- University of California Los Angeles Prostate Cancer Index, 396
- Uterine cancer, screening for, as therapy complication, 344
- V gene, 136  
 analysis of, 137-138
- V-ICE chemotherapy regimen, in small cell lung cancer, 14-15
- Vaccination therapy  
 in nicotine addiction, 100  
 in small cell lung cancer, 82-83
- Vaccine, tumor, dendritic cell, 649, 651
- Validation, 573-574  
 cross-, 574  
 definition of, 572
- Vascular endothelial growth factor, 263-264  
 in prostate cancer, 589
- Vasomotor symptoms, in breast cancer survivors, 781-785
- Vegetables, potentially anticarcinogenic substances in, 88
- Velaripride, 782
- Venlafaxine, 782, 784
- Verbal ability, following chemotherapy, 750
- Verbal learning, following chemotherapy, 750
- VH gene usage, 134
- Vinblastine, adjuvant, leukemia following, 744
- Vinblastine, estramustine regimen, in prostate cancer, 565
- Vincristine  
 in dose-intensity trial, 13  
 neurotoxicity due to, 755
- Vinorelbine, 73  
 in small cell lung cancer, 17-18
- Visilizumab, 514
- Visual memory, following chemotherapy, 750
- Vitamin C, 793
- Vitamin D, in prostate cancer, 691-692
- Vitamin D receptor, 698
- Vitamin D response elements, 698
- Vitamin D3, 697-698  
 mechanisms of action of, 700-701
- Volume effect, 599
- Waldenstrom, Dr Jan Gosta, 107
- Waldenstrom's macroglobulinemia  
 age in, stem cell transplantation and, 287-288  
 angiogenesis in, 262-263  
 anti-CD22 monoclonal antibodies in, 255  
 asymptomatic, 117, 206-210  
 autologous transplantation in, 284, 294  
 B lymphocyte immunophenotypes in, 189-190  
 Bcl-2 antisense therapy in, 297-299  
 beta2-microglobulin levels in, 118  
 CD20<sup>+</sup> B cells in, 134-135  
 characterization of, 116  
 chlorambucil in, 236-238  
 chromosome abnormalities in, 143  
 cladribine in, 237, 243-247  
 clarithromycin, thalidomide, dexamethasone therapy in, 270-273  
 classification of, 113  
 clinical characteristics in, 227-228  
 clinical features of, 188  
 clinicopathological definition of, 110-111  
 clonal B cells in, immunophenotypic profile of, 192  
 clonal origins in, 139-140  
 clonotypic IgM VDJ signature in, 134  
 combination chemotherapy in, 123  
 combination serotherapy in, 249, 251  
 conventional cytogenetic studies in, 142-143  
 cytogenetic abnormalities in, 113-114  
 cytomorphology in, 112  
 defective apoptosis in, 161-163  
 definition of, 107-109  
 diagnostic criteria for, 112, 114, 199  
 differential diagnosis of, 201-202  
 Dutcher bodies in, 183  
 epidemiology of, 146  
 factors predicting survival in, 118  
 familial, *see* Familial Waldenstrom's macroglobulinemia  
 first-line therapy of, 121-122  
 fludarabine in, 237, 239-241  
 genomic stability in, 143-144

Waldenstrom's macroglobulinemia (*Continued*)

- genotypic features of, 198
- hematological features of, 188
- hemoglobin levels in, 118
- high-dose chemotherapy in, 123
- high-dose chemotherapy with autologous transplantation in, 282-284, 291-295
- hyaluronan in, 165-167
- IgH translocations in, 142
- IgM multiple myeloma v, 153-155
- immunoglobulin M concentration in, 196-197
- immunophenotypic definition of, 112-113
- immunophenotypic features of, 197-198
- immunophenotypic studies of, 185, 188-189
- interphase FISH in, 143, 144
- karyotype analysis in, 144
- mantle cell lymphoma mimicking phenotypes of, 186
- monoclonal antibody therapy in, 248-251
- morphologic variants of, 184
- morphological features of, 197-198
- most common phenotypic profiles in, 190
- multiple myeloma response criteria and, 329-331
- oblimersen sodium in, 297-299, 300-303
- phenotypic analysis of, 133-134
- phenotypic characterization of, 132
- plasma cells in, 183
- plasmacytoid lymphocytes in, 183
- prognostic factors in, 245-247
- prognostic markers in, 118
- prognostic scoring system in, 117-118
- proteomic studies in, 156-159
- radioimmunotherapy in, 258-260
- refractory, treatment of, 239-240
- relapsed, therapy of, 122-123, 239-240
- rituximab therapy in, 440
- serotherapy in, 248-251
- short term treatment in, 118
- small lymphocytes in, 183

Waldenstrom's macroglobulinemia (*Continued*)

- smoldering, *see* Smoldering Waldenstrom's macroglobulinemia
  - staging system for, 112-113
  - survival in, 209, 212, 213-214
  - thalidomide therapy in, 265-268
  - therapy initiation in, 119
  - tumor vaccination in, 307
  - uniform pathology in, 182
  - V gene analysis in, 137-138
  - watch-and-wait patients with, 119-120
  - Wayne State University preclinical model for, 313-316
  - Zevalin in, 259
- Watchful waiting
- complications of, 582
  - definition of, 591
  - in prostate cancer, 581
- Women, healthy lifestyle for, 769
- Women's Healthy Eating and Living Study, 795
- Women's Intervention Nutrition Study, 794-795
- World Health Organization classification
- of small cell lung cancer, 3-4
  - of Waldenstrom's macroglobulinemia, 107-108
- XIAP, 428
- YM 598, 678
- Yttrium 90-epratuzumab, 459-460
- Yttrium 90-ibritumomab tiuxetan, 444, 453, 534-538
- expanded applications of, 538
- ZD1839, in small cell lung cancer, 76
- Zeaxanthin, chemical structure of, 87
- Zevalin, 256, 258
- phase I trial of, 259-260
  - in Waldenstrom's macroglobulinemia, 259
- Zoledronate, 770
- Zoledronic acid, 692